Risedronate Sodium Tablet, Film Coated
Product Images NDC 33342-109

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Risedronate Sodium (NDC 33342-109). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Macleods Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Srtuct (Risedronate Structure)

Chemical structure of Risedronate Sodium, showing its molecular arrangement including phosphate groups, a pyridine ring, and associated hydration (2.5 molecules of water).*

FDA Label Image

123 (Risedronate Fig 1)

A bar chart titled 'Nonvertebral Osteoporosis-Related Fractures Cumulative Incidence Over 3 Years Combined VERT MN and VERT NA.' It compares the percentage of patients experiencing fractures at various sites—including all sites, wrist, humerus, hip, pelvis, leg, and clavicle—between placebo and risedronate sodium tablets 5 mg groups. The chart shows lower fracture rates for the risedronate group compared to placebo across most fracture sites.*

FDA Label Image

456 (Risedronate Fig 2)

A bar graph titled 'Figure 2 Change in BMD from Baseline 2-Year Prevention Study' comparing mean percentage changes in bone mineral density (BMD) at three sites: Lumbar Spine, Femoral Neck, and Femoral Trochanter. It displays data for placebo and Risedronate sodium 5 mg tablets, showing increases in BMD with Risedronate sodium relative to placebo at all sites.*

FDA Label Image

159 (Risedronate Fig 3)

A bar chart showing the mean percentage change in bone mineral density (BMD) from baseline at three anatomical sites: lumbar spine, femoral neck, and femoral trochanter. The chart compares placebo (white bars) and Risedronate Sodium 5 mg (black bars) in patients recently initiating glucocorticoid therapy, including sample sizes for each group. Error bars represent standard error.*

FDA Label Image

156 (Risedronate Fig 4)

A bar chart titled 'Change in BMD from Baseline Patients on Long-Term Glucocorticoid Therapy' comparing placebo and Risedronate Sodium 5 mg effects on bone mineral density (BMD) measurements at three anatomical sites: lumbar spine, femoral neck, and femoral trochanter. The chart depicts mean percentage changes with standard error bars for each group.*

FDA Label Image

125 (Risedronate Fig 5)

A bar graph showing the incidence percentage of vertebral fractures in patients either continuing or initiating glucocorticoid therapy. It compares placebo and Risedronate Sodium 5 mg groups with separate bars for patients continuing treatment, patients initiating treatment, and a combined group. Numeric sample sizes (n) are noted for each group.*

FDA Label Image

129 (Risedronate Fig 6)

A line graph depicting the mean percent change from baseline in serum alkaline phosphatase excess over visit days up to 600 days, comparing DIDRONE 400 mg and Risedronate Sodium 30 mg treatments. The graph shows percent change on the Y-axis and visit days on the X-axis during treatment, follow-up, and extended follow-up periods, with sample sizes indicated for each time point.*

FDA Label Image

505 (Risedronate 5mg 30s)

Label for Risedronate Sodium Tablets USP 5 mg, film-coated oral tablets by Macleods Pharmaceuticals Limited. The label shows the dosage strength (5 mg), manufacturer details including Macleods Pharma USA, Inc., and storage instructions. It includes barcodes and mentions a 30-tablet count.*

FDA Label Image

505 (Risedronate 5mg 2000s)

Risedronate Sodium 5 mg film-coated tablets label from Macleods Pharmaceuticals Limited. The label shows the drug name with strength prominently, prescribing and storage information, and the quantity of 2000 tablets. The label also includes barcodes, manufacturer details, and dosing advisory for pharmacists.*

FDA Label Image

505 (Risedronate 5mg 30s Carton)

Packaging label for Risedronate Sodium Tablets, USP 5 mg film-coated oral tablets. The label shows a 30 tablet count (3 bottles of 10 unit-dose tablets) manufactured by Macleods Pharmaceuticals Limited. It includes storage instructions and a barcode, with emphasis on the 5 mg strength and once-a-day dosing.*

FDA Label Image

505 (Risedronate 30mg 30s)

Risedronate Sodium Tablets, USP 30 mg film-coated tablet label by Macleods Pharmaceuticals Limited. The label includes dosage strength, manufacturer details, storage instructions, and a bar code. It indicates a 30-tablet bottle with oral dosage form for prescription use.*

FDA Label Image

505 (Risedronate 30mg 500s)

Label for Risedronate Sodium Tablets, USP 30 mg, film-coated oral tablets. The label includes dosage strength, a barcode, manufacturer information identifying Macleods Pharmaceuticals Limited and Macleods Pharma USA, Inc., directions to consult prescribing information, storage conditions, and a patient medication guide website.*

FDA Label Image

505 (Risedronate 30mg 30s Carton)

Packaging label for Risedronate Sodium Tablets, USP 30 mg film-coated oral tablets. The label shows Macleods Pharma USA as the manufacturer and Macleods Pharmaceuticals Ltd. in India as the manufacturer site, with a package containing 30 tablets (3 x 10 unit-dose tablets). Storage instructions and usual dosage reference are included.*

FDA Label Image

505 (Risedronate 35mg 4s Carton)

Packaging label for Risedronate Sodium Tablets, USP 35 mg film-coated tablets by Macleods Pharmaceuticals Limited. The label specifies a 4-week supply containing 4 tablets, intended for oral use once a week. The label includes usage instructions, storage conditions, manufacturer details, and a barcode.*

FDA Label Image

505 (Risedronate 35mg 12s Carton)

Packaging label for Risedronate Sodium Tablets, USP, 35 mg film-coated tablets, manufactured by Macleods Pharmaceuticals Ltd. and labeled for Macleods Pharma USA, Inc. The carton includes directions for opening the blister pack and administration instructions highlighting weekly dosage, including taking one tablet in the morning with water and not lying down for 30 minutes after.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.